Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thioridazine for dementia.

V Kirchner1, A Kelly C, R J Harvey

  • 1Dementia Research Group, Institute of Neurology, The National Hospital for Neurology & Neurosurgery, Queen Square, London, UK, WC1N 3BG. r.harvey@dementia.ion.ucl.ac.uk

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left-lateral laparotomy using a dorsoventral incision for unilateral ovariohysterectomy in free-ranging African lions (<i>Panthera leo</i>).

Journal of the South African Veterinary Association·2025
Same author

Operation Sahel: translocation and reintroduction of West African giraffe (<i>Giraffa camelopardalis peralta</i>) in Niger.

Journal of the South African Veterinary Association·2025
Same author

Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis.

Allergy·2024
Same author

Immobilisation protocols for wild giraffe <i>(Giraffa spp.)</i>- a review.

Journal of the South African Veterinary Association·2024
Same author

Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study.

Rhinology·2023
Same author

Protocolized screening and detection of occult alcohol use before and after liver transplant: Lessons learned from a quality improvement initiative.

Clinical transplantation·2023
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Limited evidence supports thioridazine for dementia. While it may reduce anxiety, it offers no significant cognitive benefits and carries risks of adverse effects, questioning its widespread use in elderly patients.

Area of Science:

  • Geriatric Medicine
  • Psychopharmacology
  • Clinical Neurology

Background:

  • Neuroleptic drugs in dementia are controversial due to potential clinical decline.
  • Thioridazine, a commonly prescribed phenothiazine neuroleptic, is favored for fewer motor side effects but has significant sedative and anticholinergic properties.
  • Anticholinergic effects may negatively impact cognitive function in dementia patients.

Purpose of the Study:

  • To evaluate the evidence for thioridazine use in dementia.
  • Assess efficacy in symptom control.
  • Determine cognitive outcomes and safety profiles.

Main Methods:

  • Searched Cochrane Controlled Trials Register and other databases for 'thioridazine', 'melleril', 'dementia', 'old age'.
  • Included unconfounded, single- or double-blind, randomized trials comparing thioridazine to alternatives in dementia patients.

Related Experiment Videos

  • Extracted data on final assessment scores, changes from baseline, and adverse events; pooled data using meta-analysis.

    • Main Results:

    • Thioridazine reduced anxiety symptoms compared to placebo (Hamilton Anxiety Scale).
    • No significant effect on global clinical change; trend for higher adverse effects versus placebo.
    • Showed similar or worse outcomes compared to diazepam, chlormethiazole, and other neuroleptics, with increased dizziness.

    Conclusions:

    • Inadequate evidence supports current widespread use of thioridazine in dementia.
    • The only demonstrated benefit is anxiety reduction; it offers no cognitive improvement.
    • Clinicians should be aware of limited evidence and potential for excess side effects.